BioCryst Pharmaceuticals (BCRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.35
- Estimate
- $0.24
- Surprise
- +49.4%
- Revenue (period 2026-06-30)
- $218.3M
- Score at report (before → after)
- 6.5 → 6.3/10
Revenue source: xbrl.
How the report landed
BioCryst Pharmaceuticals (BCRX) beat the $0.24 estimate with diluted EPS of $0.35 — a large 49.4% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.5/10) to Hold at 6.3/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BCRX Sell at 7.3/10.
4 of the last 4 quarters beat the estimate; this quarter's +49.4% surprise compares with a +100.0% four-quarter average. Next scheduled report: 2026-11-02.
What argues against it
- Risk below floor (2.3 < 3.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.42
- Price target
- $17.95
- Stop
- $7.84
- Upside to target
- +113.2%
- Reward-to-risk
- 12.1:1
Risk check: RSI 28 — a level conventionally read as oversold; trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
BCRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $2.09B
- P/E (fwd)
- 8.7
- 52-week range
- $6.00–$11.22
- Off 52-week high
- 25.0%
- RSI (14)
- 28
- Volume vs avg
- 1.55×
- Score today
- 7.3/10